ADCS Prevention Instrument Project: Quality of life assessment (QOL)

Marian B. Patterson, Peter J. Whitehouse, Steven D. Edland, Susie A. Sami, Mary Sano, Kathleen Smyth, Myron F. Weiner

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Information about quality of life (QOL) is valuable in evaluating pharmaceutical agents but it is not adequately assessed in many dementia drug trials. In prevention trials, following participants to conversion to AD requires QOL scales appropriate for both normal and cognitively impaired individuals. Our objective was to evaluate the utility of several scales for subject or informant QOL assessment: Quality of Life-AD; Quality of Life Activity Inventory; SF-36; SF-12 (a shortened version of the SF-36); and Satisfaction with Life Scale. Measurements were collected from 644 subject-study partner pairs, half of whom completed the instruments at the clinic and half at home. Three-month test-retest data were collected. Scales administered at home or in clinic did not differ significantly. Subject self-ratings showed a wide range for all scales. Test-retest intraclass coefficients ranged from 0.67 to 0.77. Moderately high interscale associations suggest that the scales are measuring common aspects of QOL but are not equivalent. Furthermore, they differed with respect to associations with demographic variables and QOL determinants. We conclude that the QOL scores at baseline show sufficient range and reliability to suggest they will have utility in tracking QOL through conversion to dementia.

Original languageEnglish (US)
JournalAlzheimer Disease and Associated Disorders
Volume20
Issue numberSUPPL. 3
DOIs
StatePublished - Oct 2006

Fingerprint

Quality of Life
Dementia
Pharmaceutical Preparations
Demography
Equipment and Supplies

Keywords

  • Alzheimer disease
  • Assessment measures
  • Clinical trials
  • Mail-in questionnaires
  • Primary prevention
  • Quality of life

ASJC Scopus subject areas

  • Geriatrics and Gerontology
  • Psychiatry and Mental health
  • Neuroscience(all)

Cite this

Patterson, M. B., Whitehouse, P. J., Edland, S. D., Sami, S. A., Sano, M., Smyth, K., & Weiner, M. F. (2006). ADCS Prevention Instrument Project: Quality of life assessment (QOL). Alzheimer Disease and Associated Disorders, 20(SUPPL. 3). https://doi.org/10.1097/01.wad.0000213874.25053.e5

ADCS Prevention Instrument Project : Quality of life assessment (QOL). / Patterson, Marian B.; Whitehouse, Peter J.; Edland, Steven D.; Sami, Susie A.; Sano, Mary; Smyth, Kathleen; Weiner, Myron F.

In: Alzheimer Disease and Associated Disorders, Vol. 20, No. SUPPL. 3, 10.2006.

Research output: Contribution to journalArticle

Patterson, MB, Whitehouse, PJ, Edland, SD, Sami, SA, Sano, M, Smyth, K & Weiner, MF 2006, 'ADCS Prevention Instrument Project: Quality of life assessment (QOL)', Alzheimer Disease and Associated Disorders, vol. 20, no. SUPPL. 3. https://doi.org/10.1097/01.wad.0000213874.25053.e5
Patterson, Marian B. ; Whitehouse, Peter J. ; Edland, Steven D. ; Sami, Susie A. ; Sano, Mary ; Smyth, Kathleen ; Weiner, Myron F. / ADCS Prevention Instrument Project : Quality of life assessment (QOL). In: Alzheimer Disease and Associated Disorders. 2006 ; Vol. 20, No. SUPPL. 3.
@article{35309177444a4818bf7efbd9621f3bfe,
title = "ADCS Prevention Instrument Project: Quality of life assessment (QOL)",
abstract = "Information about quality of life (QOL) is valuable in evaluating pharmaceutical agents but it is not adequately assessed in many dementia drug trials. In prevention trials, following participants to conversion to AD requires QOL scales appropriate for both normal and cognitively impaired individuals. Our objective was to evaluate the utility of several scales for subject or informant QOL assessment: Quality of Life-AD; Quality of Life Activity Inventory; SF-36; SF-12 (a shortened version of the SF-36); and Satisfaction with Life Scale. Measurements were collected from 644 subject-study partner pairs, half of whom completed the instruments at the clinic and half at home. Three-month test-retest data were collected. Scales administered at home or in clinic did not differ significantly. Subject self-ratings showed a wide range for all scales. Test-retest intraclass coefficients ranged from 0.67 to 0.77. Moderately high interscale associations suggest that the scales are measuring common aspects of QOL but are not equivalent. Furthermore, they differed with respect to associations with demographic variables and QOL determinants. We conclude that the QOL scores at baseline show sufficient range and reliability to suggest they will have utility in tracking QOL through conversion to dementia.",
keywords = "Alzheimer disease, Assessment measures, Clinical trials, Mail-in questionnaires, Primary prevention, Quality of life",
author = "Patterson, {Marian B.} and Whitehouse, {Peter J.} and Edland, {Steven D.} and Sami, {Susie A.} and Mary Sano and Kathleen Smyth and Weiner, {Myron F.}",
year = "2006",
month = "10",
doi = "10.1097/01.wad.0000213874.25053.e5",
language = "English (US)",
volume = "20",
journal = "Alzheimer Disease and Associated Disorders",
issn = "0893-0341",
publisher = "Lippincott Williams and Wilkins",
number = "SUPPL. 3",

}

TY - JOUR

T1 - ADCS Prevention Instrument Project

T2 - Quality of life assessment (QOL)

AU - Patterson, Marian B.

AU - Whitehouse, Peter J.

AU - Edland, Steven D.

AU - Sami, Susie A.

AU - Sano, Mary

AU - Smyth, Kathleen

AU - Weiner, Myron F.

PY - 2006/10

Y1 - 2006/10

N2 - Information about quality of life (QOL) is valuable in evaluating pharmaceutical agents but it is not adequately assessed in many dementia drug trials. In prevention trials, following participants to conversion to AD requires QOL scales appropriate for both normal and cognitively impaired individuals. Our objective was to evaluate the utility of several scales for subject or informant QOL assessment: Quality of Life-AD; Quality of Life Activity Inventory; SF-36; SF-12 (a shortened version of the SF-36); and Satisfaction with Life Scale. Measurements were collected from 644 subject-study partner pairs, half of whom completed the instruments at the clinic and half at home. Three-month test-retest data were collected. Scales administered at home or in clinic did not differ significantly. Subject self-ratings showed a wide range for all scales. Test-retest intraclass coefficients ranged from 0.67 to 0.77. Moderately high interscale associations suggest that the scales are measuring common aspects of QOL but are not equivalent. Furthermore, they differed with respect to associations with demographic variables and QOL determinants. We conclude that the QOL scores at baseline show sufficient range and reliability to suggest they will have utility in tracking QOL through conversion to dementia.

AB - Information about quality of life (QOL) is valuable in evaluating pharmaceutical agents but it is not adequately assessed in many dementia drug trials. In prevention trials, following participants to conversion to AD requires QOL scales appropriate for both normal and cognitively impaired individuals. Our objective was to evaluate the utility of several scales for subject or informant QOL assessment: Quality of Life-AD; Quality of Life Activity Inventory; SF-36; SF-12 (a shortened version of the SF-36); and Satisfaction with Life Scale. Measurements were collected from 644 subject-study partner pairs, half of whom completed the instruments at the clinic and half at home. Three-month test-retest data were collected. Scales administered at home or in clinic did not differ significantly. Subject self-ratings showed a wide range for all scales. Test-retest intraclass coefficients ranged from 0.67 to 0.77. Moderately high interscale associations suggest that the scales are measuring common aspects of QOL but are not equivalent. Furthermore, they differed with respect to associations with demographic variables and QOL determinants. We conclude that the QOL scores at baseline show sufficient range and reliability to suggest they will have utility in tracking QOL through conversion to dementia.

KW - Alzheimer disease

KW - Assessment measures

KW - Clinical trials

KW - Mail-in questionnaires

KW - Primary prevention

KW - Quality of life

UR - http://www.scopus.com/inward/record.url?scp=33845388071&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845388071&partnerID=8YFLogxK

U2 - 10.1097/01.wad.0000213874.25053.e5

DO - 10.1097/01.wad.0000213874.25053.e5

M3 - Article

C2 - 17135811

AN - SCOPUS:33845388071

VL - 20

JO - Alzheimer Disease and Associated Disorders

JF - Alzheimer Disease and Associated Disorders

SN - 0893-0341

IS - SUPPL. 3

ER -